The aim of present work was to study the toxometric characteristics of a new biologically active compound — zinc-oxyethylidene diphosphonate germanium (germazin) in acute experiment after oral (or.), subcutaneous (s. c.) and intra-abdominal (i. a.) administration. It was established that germazin belongs to low-toxicity compounds (IV class toxicity) at any of the ways of administration both in rats and in mice. The calculated toxicity indexes of new germanium compound indicate that it does not possess a significant toxicity for humans. This conclusion can be drawn under the low values of LD50, acute toxic effects of the zone and so on. The studied compound has shown lower toxicity comparatively to analogue germanium compound where zinc is replaced by copper (medgerm). For example, the LD50 at i. a., s. c., and or. routes of administration new biological active compound were 47.24; 78.07 and 618.08 mg/kg versus 10.01; 11.54 and 372.59 mg/kg for medgerm. Relatively insignificant toxicity of germazin witnesses its good prospective for further pre-clinical researches as a promising medical agent.
